Non-Invasive Detection of HPV+ and Throat Cancers
Search text
About 24 results
(0.10 seconds)
Scientists from University of Pittsburgh have developed a novel approach to target cancer cells through the insertion of a “suicide gene” (HSV1-tk) into key gene fusion areas of the cancer genome. • Research has identified a panel of fusion genes present in various cancers including hepatocellular carcinoma (HCC). • This approach has been studied in TMEM135-CCDC67 in human prostate cancer highlighting this potential of genome editing to provide a genotype-specific approach to treat various cancers.
University of Pittsburgh researchers have developed a novel approach for the non-invasive detection and phenotyping of ovarian cancer using liquid biopsy. This approach allows for the accurate prediction of methylation patterns in new plasma samples, enhancing the sensitivity and specificity of ovarian cancer detection. - Early diagnosis of ovarian cancer.
Through Pan-Cancer Analysis of Whole Genomes, it has been found that IGR burden is a pivotal contributor to increased T-inflamed signature in selected tumor entities such as breast cancer, ovarian cancer, uterine corpus endometrial cancer, and esophageal adenocarcinoma, and correlates with increased type-I immune response effectors, such as Macrophage M1 and CD8+ T cells. IGR burden correlates with increased T-inflamed signature in breast, ovarian, endometrial and esophageal cancers for which TMB do not have significant predictive values. While immune checkpoint inhibitors (ICIs), which target the binding between programmed death 1 and its ligand (PD1/PD-L1), increase the survival of cancer patients, only a small subset of them receive benefits.